Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized trial of SBRT followed by iparomlimab + tuvonralimab plus chemotherapy versus tislelizumab plus chemotherapy in PD-L1-negative or low-expressing oligometastatic NSCLC
ChiCTR2600133003Phase 2Not yet recruiting
- Sponsor
- Shandong Cancer Hospital
- Start
- Sep 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of iparomlimab, tuvonralimab and tislelizumab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Shandong Cancer Hospital. Primary endpoint: Progression-free survival. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
iparomlimabtuvonralimabtislelizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2600133003.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600133003.